Cargando…

Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182631/ https://www.ncbi.nlm.nih.gov/pubmed/25268802 http://dx.doi.org/10.1371/journal.pone.0110069

Ejemplares similares

Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
por: Sha, Sue, et al.
Publicado: (2014)

Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
por: Kushner, Pamela
Publicado: (2016)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
por: Laffel, L. M. B., et al.
Publicado: (2018)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2023)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()
por: Qiu, Rong, et al.
Publicado: (2014)

Correction to: Sodium‐Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt‐Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
por: Pfeifer, Michael, et al.
Publicado: (2017)

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants
por: Devineni, Damayanthi, et al.
Publicado: (2015)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
por: Hropot, Tim, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
por: Bader, Nimrah, et al.
Publicado: (2016)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
por: Torimoto, Keiichi, et al.
Publicado: (2017)

Sodium glucose co-transporter 2 inhibitors for glycemic control in type 2 diabetes mellitus: Quality of reporting of randomized controlled trials
por: Mittal, Niti, et al.
Publicado: (2016)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
por: Sharma, M D
Publicado: (2015)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
por: Hardman, Timothy Colin, et al.
Publicado: (2011)

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
por: Evans, Marc, et al.
Publicado: (2017)

Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?
por: Giorgino, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3b6ka62va2emn12h0n8ioqrt25